FDA Approves Unknown Drug — SANDOZ

On August 1, 2008, Sandoz secured FDA approval of its Abbreviated New Drug Application (ANDA 078510), an approval that is expected to inject competition into the generic market by offering fans of the undefinied brand product a more cost-effective alternative to the original branded therapy. This development creates additional market pressure on the manufacturer of the reference product by expanding accessible production capacity and driving down market prices.